

References

1. Bostanci Y, Kazzazi A, Momtahn S, Laze J, Djavan B. Correlation between benign prostatic hyperplasia and inflammation. *Current Opin Urol* 2013;23:5-10.
2. Norström MM, Radestad E, Sundberg B, Mattsson J, Henningsohn L, Levitsky V, et al. Progression of benign prostatic hyperplasia is associated with pro-inflammatory mediators and chronic activation of prostate-infiltrating lymphocytes. *Oncotarget* 2016; 7:23581-93.
3. Roehrborn CG. Pathology of benign prostatic hyperplasia. *Int J Impot Res* 2008;20(Suppl 3):S11-8.
4. Ooi SK, Qiu C, Bernstein E, Li K, Jia D, Yang Z, et al. DNMT3L connects unmethylated lysine 4 of histone H3 to de novo methylation of DNA. *Nature* 2007;448:714-7.
5. Arand J, Spieler D, Karius T, Branco MR, Meilinger D, Meissner A, et al. In vivo control of CpG and non-CpG DNA methylation by DNA methyltransferases. *PLoS Genet* 2012;8:e1002750.
6. Niu Y, Ge R, Hu L, Diaz C, Wang Z, Wu CL, et al. Reduced levels of 5-alpha reductase 2 in adult prostate tissue and implications for BPH therapy. *Prostate* 2011;71:1317-24.
7. Ge R, Wang Z, Bechis SK, Otsetov AG, Hua S, Wu S, et al. DNA methyltransferase 1 reduces expression of SRD5A2 in the aging adult prostate. *Am J Pathol* 2015;185:870-82.
8. Bechis SK, Otsetov AG, Ge R, Olumi AF. Personalized medicine for the management of benign prostatic hyperplasia. *J Urol* 2014;192:16-23.
9. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. *Cell* 2009;139:871-90.
10. Grant CM, Kyprianou N. Epithelial mesenchymal transition (EMT) in prostate growth and tumor progression. *Transl Androl Urol* 2013;2:202-11.
11. Alonso-Magdalena P, Brossner C, Reiner A, Cheng G, Sugiyama N, Warner M, et al. A role for epithelial-mesenchymal transition in the etiology of benign prostatic hyperplasia. *Proc Natl Acad Sci U S A* 2009;106:2859-63.
12. Lu T, Lin WJ, Izumi K, Wang X, Xu D, Fang LY, et al. Targeting androgen receptor to suppress macrophage-induced EMT and benign prostatic hyperplasia (BPH) development. *Mol Endocrinol* 2012;26:1707-15.
13. Slabakova E, Pernicova Z, Slavickova E, Starsichova A, Kozubik A, Soucek K. TGF-beta1-induced EMT of non-trans-
- formed prostate hyperplasia cells is characterized by early induction of SNAI2/Slug. *Prostate* 2011;71:1332-43.
14. Sullivan NJ, Sasser AK, Axel AE, Vesuna F, Raman V, Ramirez N, et al. Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells. *Oncogene* 2009;28:2940-7.
15. Panchanathan R, Liu H, Choubey D. Hypoxia primes human normal prostate epithelial cells and cancer cell lines for the NLRP3 and AIM2 inflammasome activation. *Oncotarget* 2016; 7:28183-94.
16. Zhang Q, Chen L, Helfand BT, Jang TL, Sharma V, Kozlowski J, et al. TGF-beta regulates DNA methyltransferase expression in prostate cancer, correlates with aggressive capabilities, and predicts disease recurrence. *PLoS One* 2011;6:e25168.
17. Penna G, Fibbi B, Amuchastegui S, Cossetti C, Aquilano F, Laverny G, et al. Human benign prostatic hyperplasia stromal cells as inducers and targets of chronic immuno-mediated inflammation. *J Immunol* 2009;182:4056-64.
18. Adler HL, McCurdy MA, Kattan MW, Timme TL, Scardino PT, Thompson TC. Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. *J Urol* 1999;161:182-7.
19. Kim HJ, Park J, Cho YS, Cho CH, Kim JS, Shim H, et al. Pathogenic role of HIF-1alpha in prostate hyperplasia in the presence of chronic inflammation. *Biochim Biophys Acta* 2013;1832:183-9.
20. Schenk JM, Kristal AR, Neuhaus ML, Tangen CM, White E, Lin DW, et al. Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. *Am J Epidemiol* 2010;171:571-82.
21. Michalaki V, Syrigos K, Charles P, Waxman J. Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer. *Br J Cancer* 2004;90:2312-6.
22. Starsichova A, Lincova E, Pernicova Z, Kozubik A, Soucek K. TGF-beta1 suppresses IL-6-induced STAT3 activation through regulation of Jak2 expression in prostate epithelial cells. *Cell Signall* 2010;22:1734-44.
23. Liu TT, Grubisha MJ, Frahm KA, Wendell SG, Liu J, Ricke WA, et al. Opposing effects of cyclooxygenase-2 (COX-2) on estrogen receptor beta (ERbeta) response to 5alpha-reductase inhibition in prostate epithelial cells. *J Biol Chem* 2016; 291:14747-60.
24. Keil KP, Vezina CM. DNA methylation as a dynamic regulator of development and disease processes: spotlight on the prostate. *Epigenomics* 2015;7:413-25.
25. Keil KP, Abler LL, Mehta V, Altmann HM, Laporta J, Plisch EH, et al. DNA methylation of E-cadherin is a priming mechanism for prostate development. *Dev Biol* 2014;387:142-53.
26. Fukagawa A, Ishii H, Miyazawa K, Saitoh M. deltaEF1 associates with DNMT1 and maintains DNA methylation of the E-cadherin promoter in breast cancer cells. *Cancer Med* 2015;4:125-35.
27. Graff JR, Herman JG, Lapidus RG, Chopra H, Xu R, Jarrard DF, et al. E-cadherin expression is silenced by DNA hypomethylation in human breast and prostate carcinomas. *Cancer Res* 1995;55:5195-9.
28. Henrique R, Jeronimo C, Hoque MO, Carvalho AL, Oliveira J, Teixeira MR, et al. Frequent 14-3-3 sigma promoter methylation in benign and malignant prostate lesions. *DNA Cell Biol* 2005;24:264-9.
29. Starsichova A, Kubala L, Lincova E, Pernicova Z, Kozubik A, Soucek K. Dynamic monitoring of cellular remodeling induced by the transforming growth factor-beta1. *Biol Proced Online* 2009;11:316-24.
30. He Y, Ou Z, Chen X, Zu X, Liu L, Li Y, et al. LPS/TLR4 Signaling enhances TGF-beta response through downregulating BAMBI during prostatic hyperplasia. *Sci Rep* 2016;6:27051.
31. Cardenas H, Vieth E, Lee J, Segar M, Liu Y, Nephew KP, et al. TGF-beta induces global changes in DNA methylation during the epithelial-to-mesenchymal transition in ovarian cancer cells. *Epigenetics* 2014;9:1461-72.
32. Cao Q, Yu J, Dhanasekaran SM, Kim JH, Mani RS, Tomlins SA, et al. Repression of E-cadherin by the polycomb group protein EZH2 in cancer. *Oncogene* 2008;27:7274-84.
33. Herranz N, Pasini D, Diaz VM, Franci C, Gutierrez A, Dave N, et al. Polycomb complex 2 is required for E-cadherin repression by the Snail1 transcription factor. *Mol Cell Biol* 2008;28:4772-81.
34. Li CW, Xia W, Huo L, Lim SO, Wu Y, Hsu JL, et al. Epithelial-mesenchymal transition induced by TNF-alpha requires NF-kappaB-mediated transcriptional upregulation of Twist1. *Cancer Res* 2012;72:1290-300.